

GLAXOSMITHKLINE PLC  
Form 6-K  
August 27, 2015

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending August 2015

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

--

GlaxoSmithKline plc

Notification of Transactions of Directors, Persons Discharging Managerial Responsibilities or Connected Persons

In accordance with DTR 3.1.4R(1)(a) and (c) GlaxoSmithKline plc ('GSK') was advised on 27 August 2015 of a change in the interests of the following Person Discharging Managerial Responsibilities ('PDMR') and Connected Person, in the Ordinary Shares and American Depositary Shares ("ADS") of GSK, as a result of awards made under the GlaxoSmithKline 2009 Share Value Plan on 25 August 2015:

PDMR	Ordinary Shares Awarded
------	----------------------------

Mrs V A Whyte	11,060
---------------	--------

Connected Person	ADSs Awarded
------------------	--------------

Dr K S l a o u i (Connected Person of Dr M Slaoui)	2,530
--	-------

The closing price of an Ordinary Share on 25 August 2015 was £12.96 and the closing price of an ADS was \$39.41.

V A Whyte  
Company Secretary

27 August 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: August 27, 2015

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc